Aaron Schuchart

CIK 1709258 · Chief Business Officer · last filed 2024-12-13

Aaron Schuchart is a Chief Business Officer who has filed 13 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for LUMO, was dated Dec 13, 2024. Across all open-market trades the lifetime net is −$42.2K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

13

Lifetime Open-Market Net

-$42.2K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LUMOS PHARMA, INC. (LUMO) Delisted Chief Business Officer 0 $4.34 $0 $14.8K 7 2024-12-13
Spyre Therapeutics, Inc. (AGLE) Delisted Chief Business Officer 8,400 $12.01 $100.9K -$57.0K 6 2019-03-01

Recent Filings

13 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2024-12-13 LUMOS PHARMA, INC. (LUMO) Delisted Disp (D) −8,179 $0 EDGAR
2024-04-03 LUMOS PHARMA, INC. (LUMO) Delisted Grant (A) +1,000 $2.8K EDGAR
2024-02-05 LUMOS PHARMA, INC. (LUMO) Delisted Tax (F) −202 -$608 EDGAR
2023-02-03 LUMOS PHARMA, INC. (LUMO) Delisted Mixed +896 $3.2K EDGAR
2022-02-03 LUMOS PHARMA, INC. (LUMO) Delisted Mixed +948 $9.5K EDGAR
2021-08-13 LUMOS PHARMA, INC. (LUMO) Delisted Buy (P) +2,000 $14.8K EDGAR
2021-06-03 LUMOS PHARMA, INC. (LUMO) Delisted Grant (A) $0 EDGAR
2019-03-01 Spyre Therapeutics, Inc. (AGLE) Delisted Grant (A) $0 EDGAR
2018-09-28 Spyre Therapeutics, Inc. (AGLE) Delisted Sell (S) −6,000 -$57.0K EDGAR
2018-08-21 Spyre Therapeutics, Inc. (AGLE) Delisted Exer (M) +8,500 $29.8K EDGAR
Showing 110 of 13
Page 1 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.